Literature DB >> 25817172

Changes in vision related quality of life in patients with diabetic macular edema: ranibizumab or laser treatment?

Elif Betul Turkoglu1, Erkan Celık2, Nilgun Aksoy3, Ozlem Bursalı4, Turgay Ucak5, Gursoy Alagoz6.   

Abstract

PURPOSE: To compare the changes in vision related quality of life (VR-QoL) in patients with diabetic macular edema (DME) undergoing intravitreal ranibizumab (IVR) injection or focal/grid laser.
MATERIAL AND METHODS: In this prospective study, 70 patients with clinically significant macular edema (CSME) were randomized to undergo IVR injection (n=35) and focal/grid laser (n=35). If necessary, the laser or ranibizumab injections were repeated. Distance and near visual acuities, central retinal thickness (CRT) and The 25-item Visual Function Questionnaire (VFQ-25) were used to measure the effectiveness of treatments and VR-QoL before and after 6 months following IVR or laser treatment.
RESULTS: The demographic and clinical findings before the treatments were similar in both main groups. The improvements in distance and near visual acuities were higher in IVR group than the laser group (p<0.01). The reduction in CRT in IVR group was higher than that in laser treatment group (p<0.01). In both groups, the VFQ-25 composite score tended to improve from baseline to 6 months. And at 6th month, the changes in composite score were significantly higher in IVR group than in laser group (p<0.05). The improvements in overall composite scores were 6.3 points for the IVR group compared with 3.0 points in the laser group. Patients treated with IVR and laser had large improvements in composite scores, general vision, near and distance visual acuities in VFQ-25 at 6 months, in comparison with baseline scores, and also mental health subscale in IVR group.
CONCLUSION: Our study revealed that IVR improved not only visual acuity or CRT, but also vision related quality of life more than laser treatment in DME. And these patient-reported outcomes may play an important role in the treatment choice in DME for clinicians.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetes; Laser; Quality of life; RETİNOPATHY; Ranibizumab

Mesh:

Substances:

Year:  2015        PMID: 25817172     DOI: 10.1016/j.jdiacomp.2015.03.009

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  4 in total

1.  Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.

Authors:  James Lin; Jonathan S Chang; William E Smiddy
Journal:  Ophthalmology       Date:  2016-07-15       Impact factor: 12.079

Review 2.  The relationship between diabetic retinopathy and psychosocial functioning: a systematic review.

Authors:  Krystal Khoo; Ryan E K Man; Gwyn Rees; Preeti Gupta; Ecosse L Lamoureux; Eva K Fenwick
Journal:  Qual Life Res       Date:  2019-03-16       Impact factor: 4.147

3.  Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.

Authors:  Gianni Virgili; Mariacristina Parravano; Jennifer R Evans; Iris Gordon; Ersilia Lucenteforte
Journal:  Cochrane Database Syst Rev       Date:  2018-10-16

4.  Burden Of Treatment Among Patients Undergoing Intravitreal Injections For Diabetic Macular Oedema In Australia.

Authors:  Kimberly L Spooner; Gerry Guinan; Saskia Koller; Thomas Hong; Andrew A Chang
Journal:  Diabetes Metab Syndr Obes       Date:  2019-09-19       Impact factor: 3.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.